Generic versus branded imatinib in frontline chronic myeloid leukemia: A systematic review and meta‐analysis
HemaSphere · 2026-10 · 10 (10)
DOI: 10.1002/hem3.70479 ↗Kurz gefasst
Leserbrief in der Zeitschrift HemaSphere, online erschienen am 29.09.2026. Verfasst von Shankar Biswas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine Ivano-Frankivsk National Medical University Ivano-Frankivsk Ukraine. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Internal Medicine Ivano-Frankivsk National Medical University Ivano-Frankivsk Ukraine.
- Department of Internal Medicine New York Medical College, St. Mary's General Hospital/St. Clare's Dover New Jersey USA.
- Department of Internal Medicine Sudan University of Science and Technology Khartoum Sudan.
ORCID-Profile: Shankar Biswas, Yashasvi Srivastava
Zitieren
APA
Biswas, S., Srivastava, Y., Tummala, N., & Hamadttu, A. (2026). Generic versus branded imatinib in frontline chronic myeloid leukemia: A systematic review and meta‐analysis. HemaSphere, 10(10). https://doi.org/10.1002/hem3.70479
Vancouver
Biswas S, Srivastava Y, Tummala N, Hamadttu A. Generic versus branded imatinib in frontline chronic myeloid leukemia: A systematic review and meta‐analysis. HemaSphere. 2026;10(10). doi:10.1002/hem3.70479
BibTeX
@article{Biswas2026,
author = {Biswas, Shankar and Srivastava, Yashasvi and Tummala, Nayanika and Hamadttu, Ayman},
title = {Generic versus branded imatinib in frontline chronic myeloid leukemia: A systematic review and meta‐analysis},
journal = {HemaSphere},
year = {2026},
volume = {10},
number = {10},
doi = {10.1002/hem3.70479}
}
EUVIMED